Impact of Rivastigmine patch and capsules on activities of daily living in Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 26, Issue 1, 2011, Pages 65-71

  Grossberg, George ^a   Xiangyi Meng, ^b   Olin, Jason T ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

activities of daily living; Alzheimer's disease; Alzheimer's Disease Cooperative Study Activities of Daily Living scale; rivastigmine; transdermal patch

Indexed keywords

PLACEBO; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; DAILY LIFE ACTIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VOMITING;

EID: 79551643729     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317510391240     Document Type: Article

References (16)

1. Cummings JL, Koumaras B., Chen M., Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005 ; 3 (3). 137-148.
2. Andersen CK, Wittrup-Jensen KU, Lolk A., Andersen K., Kragh-Sorensen P. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes. 2004 ; 2: 52.
3. Exelon Capsule. Prescribing Information. 2001. http://www.pharma.us. novartis.com/product/pi/pdf/exelon.pdf. Accessed July, 2010.
4. Exelon transdermal patch. Prescribing information. 2007. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. Accessed July, 2010.
5. Corey-Bloom J., Anand R., Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998 ; 1 (1). 55-65.
6. Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 ; 318 (7184). 633-638.
7. Winblad B., Cummings J., Andreasen N., et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007 ; 22 (5). 456-467.
8. Winblad B., Grossberg G., Frolich L., et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007 ; 69 (4 suppl 1). S14 - S22.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Press, Inc ; 1994.
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ; 34 (7). 939-944.
11. Folstein MF, Folstein SE, McHugh PR ''Mini-mental state.'' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198.
12. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997 ; 11 (suppl 2). S33 - S39.
13. Allan L., McKeith I., Ballard C., Kenny RA The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dement Geriatr Cogn Disord. 2006 ; 22 (3). 230-237.
14. Small G., Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007 ; 23 (11). 2705-2713.
15. Blesa R., Ballard C., Orgogozo JM, Lane R., Thomas SK Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007 ; 69 (4 suppl 1). S23 - S28.
16. Winblad B., Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007 ; 22 (5). 485-491.